A separate analysis of older (≥60) AML patients was able to show dramatically different outcomes for patients treated with traditional 7 + 3 induction chemotherapy, when the mutational status of seven genes (NPM1, ASXL1, DNMT3A, FLT3‐ITD, NRAS, TP53, KRAS) was added to traditional cytogenetics to create the ALFA decision model, which was validated among a three large (n = 830) cohorts [89]. This evidence concerns the gene ASXL1 and acute myeloid leukemia.